endosergЭндокринная хирургияEndocrine Surgery2306-35132310-3965Типография «Печатных дел Мастер»10.14341/serg12452endoserg-12452Research ArticleОбзоры литературыReview of literatureПерспективные иммуногистохимические и циркулирующие маркеры инсулиномыPromising immunohistochemical and circulating markers of insulinomahttps://orcid.org/0000-0002-8771-8300ЮкинаМарина ЮрьевнаYukinaMarina Yu.

к.м.н.

MD, PhD

kuronova@yandex.ruhttps://orcid.org/0000-0001-6891-0009СеливановаЛилия СергеевнаSelivanovaLiliya S.

кандидат медицинских наук, научный сотрудник отдела фундаментальной патоморфологии

MD, PhD

liselivanova89@yandex.ruhttps://orcid.org/0000-0001-6876-3336НуралиеваНурана ФейзуллаевнаNuralievaNurana F.Dr.NuralievaNF@yandex.ruhttps://orcid.org/0000-0002-8520-8702ТрошинаЕкатерина АнатольевнаTroshinaEkaterina A.

д.м.н., проф., член-корр. РАН

MD, PhD, professor, corresponding member of the RAS

troshina@imbox.ruhttps://orcid.org/0000-0002-4713-5661ИзмайловаНаталья СергеевнаIzmailovaNatalya S.

кандидат медицинских наук, научный сотрудник отдела фундаметальной морфологии

MD, PhD

nizm2013@mail.ruhttps://orcid.org/0000-0001-8284-9996АбросимовАлександр ЮрьевичAbrosimovAleksandr Yu.

Зав. отделением патоморфологии, дмн, главный научный сотрудник

MD, PhD

nikitarusskikh@mail.ruНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian Federation2020170820201411421Copyright © Юкина М.Ю., Селиванова Л.С., Нуралиева Н.Ф., Трошина Е.А., Измайлова Н.С., Абросимов А.Ю., 20202020Юкина М.Ю., Селиванова Л.С., Нуралиева Н.Ф., Трошина Е.А., Измайлова Н.С., Абросимов А.Ю.Yukina M.Y., Selivanova L.S., Nuralieva N.F., Troshina E.A., Izmailova N.S., Abrosimov A.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surg-endojournals.ru/jour/article/view/12452

Инсулинома — это наиболее часто встречающаяся функционирующая панкреатическая нейроэндокринная опухоль. В обзоре рассматриваются применяемые в настоящее время иммуногистохимические и циркулирующие маркеры для ее диагностики, обсуждаются чувствительность и специфичность данных параметров. Вместе с тем подчеркивается актуальность поиска новых биохимических показателей наличия инсулиномы и ее характеристик, а также изучения механизмов опухолевого роста и гормональной гиперсекреции. Одним из первостепенных методов решения данных задач является иммуногистохимическое тестирование с определением циркулирующих маркеров. Приводятся результаты последних исследований альтернативных секреторных продуктов, в частности, кокаин- и амфетамин-регулируемого транскрипта (CART), хромогранина В, нейроэндокринного секреторного протеина 55 (NESP55). Кроме того, рассматривается вопрос экспрессии различных рецепторов в ткани инсулиномы, в том числе в контексте определения молекулярных мишеней для ее визуализации или радиотерапии. В частности, охарактеризована экспрессия рецепторов к глюкагоноподобному пептиду 1 в ткани опухоли. Уточняется возможная роль рецепторов к мелатонину МТ1 (MTNR1a) и МТ2 (MTNR1b) в патогенезе инсулиномы. Также в статье обсуждается возможное применение опухолевого протеина D52 (TPD52) в качестве нового прогностического биомаркера для дифференциальной диагностики доброкачественной и злокачественной инсулиномы.

Insulinoma is the most common functioning pancreatic neuroendocrine tumor. The review examines the currently used immunohistochemical and circulating markers for its diagnosis, and discusses the sensitivity and specificity of these parameters. At the same time, the relevance of searching for new biochemical indicators of the presence of insulinoma and its characteristics, as well as studying the mechanisms of tumor growth and hormonal hypersecretion is emphasized. One of the primary methods for solving these problems is immunohistochemical testing with the determination of circulating markers. The results of recent studies of alternative secretory products, in particular, cocaine - and amphetamine - regulated transcript (CART), chromogranin B, and neuroendocrine secretory protein 55 (NESP55) are presented. In addition, the question of expression of various receptors in the insulinoma tissue is considered, including in the context of determining molecular targets for its visualization or radiotherapy. In particular, the expression of receptors for glucagon-like peptide 1 in the tumor tissue is characterized. The possible role of melatonin receptors MT1 (MTNR1a) and MT2 (MTNR1b) in the pathogenesis of insulinoma is clarified. The article also discusses the possible use of tumor protein D52 (TPD52) as a new predictive biomarker for the differential diagnosis of benign and malignant insulinoma.

инсулиноманейроэндокринная опухольиммуногистохимиябиомаркерыInsulinomaneuroendocrine tumorimmunohistochemistrybiomarkersРабота проведена в рамках выполнения государственного задания «Наследственные опухолевые синдромы и множественные эндокринные неоплазии: персонализация диагностики и лечения, прогнозирование рисков, идентификация ядерных семей» на 2018–2020 гг.The work was carried out within the framework of the state assignment "Hereditary tumor syndromes and multiple endocrine neoplasias: personalization of diagnosis and treatment, risk prediction, identification of nuclear families" for 2018–2020.ReferencesGiovanella LC. Chromogranin A. A circulating neuroendocrine marker biology, pathology, assay technology and clinical applications. France: CIS bio international; 2005.Giovanella LC. Chromogranin A. A circulating neuroendocrine marker biology, pathology, assay technology and clinical applications. France: CIS bio international; 2005.Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342. Doi: 10.1001/jamaoncol.2017.0589.Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342. Doi: 10.1001/jamaoncol.2017.0589.Ramachandran R, Bech P, Murphy KG, et al. Comparison of the utility of cocaine- and amphetamine-regulated transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression. J Clin Endocrinol Metab. 2016;100(4):1520–1528. Doi: 10.1210/jc.2014-3640.Ramachandran R, Bech P, Murphy KG, et al. Comparison of the utility of cocaine- and amphetamine-regulated transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression. J Clin Endocrinol Metab. 2016;100(4):1520–1528. Doi: 10.1210/jc.2014-3640.Maxwell JE, Dorisio TMO, Howe JR. Biochemical diagnosis and preoperative imaging of gastroenteropancreatic neuroendocrine tumors. Surg Oncol Clin N Am. 2016;25(1):171–194. Doi: 10.1016/j.soc.2015.08.008.Maxwell JE, Dorisio TMO, Howe JR. Biochemical diagnosis and preoperative imaging of gastroenteropancreatic neuroendocrine tumors. Surg Oncol Clin N Am. 2016;25(1):171–194. Doi: 10.1016/j.soc.2015.08.008.Mckenna LR, Edil BH. Update on pancreatic neuroendocrine tumors. Gland Surg. 2014;3(4):258–275. Doi: 10.3978/j.issn.2227-684X.2014.06.03.Mckenna LR, Edil BH. Update on pancreatic neuroendocrine tumors. Gland Surg. 2014;3(4):258–275. Doi: 10.3978/j.issn.2227-684X.2014.06.03.Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–171. Doi: 10.1159/000443171.Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–171. Doi: 10.1159/000443171.Tümör N, Genel B, Bakış B, et al. An overview of neuroendocrine tumour markers. Turkish journal of endocrinology and metabolism. 2014;18(4):132–136. Doi: 10.4274/tjem.2422.Tümör N, Genel B, Bakış B, et al. An overview of neuroendocrine tumour markers. Turkish journal of endocrinology and metabolism. 2014;18(4):132–136. Doi: 10.4274/tjem.2422.Kyriakopoulos G, Mavroeidi V, Chatzellis E, et al. Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms. Ann Transl Med. 2018;6(12):252. Doi: 10.21037/atm.2018.06.27.Kyriakopoulos G, Mavroeidi V, Chatzellis E, et al. Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms. Ann Transl Med. 2018;6(12):252. Doi: 10.21037/atm.2018.06.27.Ángel J, Pérez D, Freixes MC. Chromogranin A and neuroendocrine tumors. Endocrinol Nutr. 2013;60(7):386–395. Doi: 10.1016/j.endonu.2012.10.003.Ángel J, Pérez D, Freixes MC. Chromogranin A and neuroendocrine tumors. Endocrinol Nutr. 2013;60(7):386–395. Doi: 10.1016/j.endonu.2012.10.003.Qiao X, Qiu L, Chen Y, et al. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord. 2014;14:64. Doi: 10.1186/1472-6823-14-64.Qiao X, Qiu L, Chen Y, et al. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord. 2014;14:64. Doi: 10.1186/1472-6823-14-64.Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2011;18 Suppl 1:S17–S25. Doi: 10.1530/ERC-10-0280.Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2011;18 Suppl 1:S17–S25. Doi: 10.1530/ERC-10-0280.Bech PR, Martin NM, Ramachandran R, Bloom SR. The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia. Ann Clin Biochem. 2013;51(Pt 1):8–21. Doi: 10.1177/0004563213489670.Bech PR, Martin NM, Ramachandran R, Bloom SR. The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia. Ann Clin Biochem. 2013;51(Pt 1):8–21. Doi: 10.1177/0004563213489670.Ardill JES, O’Dorisio TM. Circulaing biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators. Endocrinol Metab Clin N Am. 2010;39(4):777–790. Doi: 10.1016/j.ecl.2010.09.001.Ardill JES, O’Dorisio TM. Circulaing biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators. Endocrinol Metab Clin N Am. 2010;39(4):777–790. Doi: 10.1016/j.ecl.2010.09.001.Bech P, Winstanley V, Murphy KG, et al. Elevated cocaine- and amphetamine-regulated transcript immunoreactivity in the circulation of patients with neuroendocrine malignancy. J Clin Endocrinol Metab. 2008;93(4):1246–1253. Doi: 10.1210/jc.2007-1946.Bech P, Winstanley V, Murphy KG, et al. Elevated cocaine- and amphetamine-regulated transcript immunoreactivity in the circulation of patients with neuroendocrine malignancy. J Clin Endocrinol Metab. 2008;93(4):1246–1253. Doi: 10.1210/jc.2007-1946.Jensen PB, Kristensen P, Clausen JT, et al. The hypothalamic satiety peptide CART is expressed in anorectic and non-anorectic pancreatic islet tumors and in the normal islet of Langerhans. FEBS Lett. 1999;447(2–3):139–143. Doi: 10.1016/s0014-5793(99)00291-4.Jensen PB, Kristensen P, Clausen JT, et al. The hypothalamic satiety peptide CART is expressed in anorectic and non-anorectic pancreatic islet tumors and in the normal islet of Langerhans. FEBS Lett. 1999;447(2–3):139–143. Doi: 10.1016/s0014-5793(99)00291-4.Sathanoori R, Erlinge D, Wierup N. Cocaine- and amphetamine-regulated transcript (CART) protects beta cells against glucotoxicity and increases cell. J Biol Chem. 2013;288(5):3208–3218. Doi: 10.1074/jbc.M112.437145.Sathanoori R, Erlinge D, Wierup N. Cocaine- and amphetamine-regulated transcript (CART) protects beta cells against glucotoxicity and increases cell. J Biol Chem. 2013;288(5):3208–3218. Doi: 10.1074/jbc.M112.437145.Wierup N, Sundler F. CART is a novel islet regulatory peptide. Peptides. 2006;27(8):2031–2036. Doi: 10.1016/j.peptides.2006.02.011.Wierup N, Sundler F. CART is a novel islet regulatory peptide. Peptides. 2006;27(8):2031–2036. Doi: 10.1016/j.peptides.2006.02.011.Bargsten G. Cytological and immunocytochemical characterization of the insulin secreting insulinoma cell line RINm5F. Arch Histol Cytol. 2004;67(1):79–94. Doi: 10.1679/aohc.67.79.Bargsten G. Cytological and immunocytochemical characterization of the insulin secreting insulinoma cell line RINm5F. Arch Histol Cytol. 2004;67(1):79–94. Doi: 10.1679/aohc.67.79.Stridsberg M, Oberg K, Li Q, et al. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol. 1995;144(1):49–59. Doi: 10.1677/joe.0.1440049.Stridsberg M, Oberg K, Li Q, et al. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol. 1995;144(1):49–59. Doi: 10.1677/joe.0.1440049.Jakobsen AM, Ahlman H, Ko L. NESP55, a novel chromogranin-like peptide, is expressed in endocrine tumours of the pancreas and adrenal medulla but not in ileal carcinoids. Br J Cancer. 2003;88(11):1746–1754. Doi: 10.1038/sj.bjc.6600924.Jakobsen AM, Ahlman H, Ko L. NESP55, a novel chromogranin-like peptide, is expressed in endocrine tumours of the pancreas and adrenal medulla but not in ileal carcinoids. Br J Cancer. 2003;88(11):1746–1754. Doi: 10.1038/sj.bjc.6600924.Korner M. Specific biology of neuroendocrine tumors: peptide receptors as molecular targets. Best Pract Res Clin Endocrinol Metab. 2016;30(1):19–31. Doi: 10.1016/j.beem.2016.01.001.Korner M. Specific biology of neuroendocrine tumors: peptide receptors as molecular targets. Best Pract Res Clin Endocrinol Metab. 2016;30(1):19–31. Doi: 10.1016/j.beem.2016.01.001.Waser B, Blank A, Karamitopoulou E, et al. Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Mod Pathol. 2015;28(3):391–402. Doi: 10.1038/modpathol.2014.113.Waser B, Blank A, Karamitopoulou E, et al. Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Mod Pathol. 2015;28(3):391–402. Doi: 10.1038/modpathol.2014.113.Luo Y, Pan Q, Yao S, et al. Glucagon-like peptide-1 receptor PET/CT with 68ga-nota-exendin-4 for detecting localized insulinoma: a prospective cohort study. J Nucl Med. 2016;57(5):715–720. Doi: 10.2967/jnumed.115.167445.Luo Y, Pan Q, Yao S, et al. Glucagon-like peptide-1 receptor PET/CT with 68ga-nota-exendin-4 for detecting localized insulinoma: a prospective cohort study. J Nucl Med. 2016;57(5):715–720. Doi: 10.2967/jnumed.115.167445.Wild D, Christ E, Caplin ME, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med. 2011;52(7):1073–1078. Doi: 10.2967/jnumed.110.085142.Wild D, Christ E, Caplin ME, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med. 2011;52(7):1073–1078. Doi: 10.2967/jnumed.110.085142.Peschke E, Mühlbauer E. New evidence for a role of melatonin in glucose regulation. Best Pract Res Clin Endocrinol Metab. 2016;24(5):829–841. Doi: 10.1016/j.beem.2010.09.001.Peschke E, Mühlbauer E. New evidence for a role of melatonin in glucose regulation. Best Pract Res Clin Endocrinol Metab. 2016;24(5):829–841. Doi: 10.1016/j.beem.2010.09.001.Peschke E, Bähr I, Mühlbauer E. Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. Int J Mol Sci. 2013;14(4):6981–7015. Doi: 10.3390/ijms14046981.Peschke E, Bähr I, Mühlbauer E. Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. Int J Mol Sci. 2013;14(4):6981–7015. Doi: 10.3390/ijms14046981.Mühlbauer E, Albrecht E, Bazwinsky-Wutschke I, Peschke E. Melatonin influences insulin secretion primarily via MT(1) receptors in rat insulinoma cells (INS-1) and mouse pancreatic islets. J Pineal Res. 2012;52(4):446–459. Doi: 10.1111/j.1600-079X.2012.00959.x.Mühlbauer E, Albrecht E, Bazwinsky-Wutschke I, Peschke E. Melatonin influences insulin secretion primarily via MT(1) receptors in rat insulinoma cells (INS-1) and mouse pancreatic islets. J Pineal Res. 2012;52(4):446–459. Doi: 10.1111/j.1600-079X.2012.00959.x.Li Y, Wu H, Liu N, et al. Melatonin exerts an inhibitory effect on insulin gene transcription via MTNR1B and the downstream Raf-1/ERK signaling pathway. Int J Mol Med. 2018;41(2):955–961. Doi: 10.3892/ijmm.2017.3305.Li Y, Wu H, Liu N, et al. Melatonin exerts an inhibitory effect on insulin gene transcription via MTNR1B and the downstream Raf-1/ERK signaling pathway. Int J Mol Med. 2018;41(2):955–961. Doi: 10.3892/ijmm.2017.3305.Alkatout I, Friemel J, Sitek B, et al. Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas. Mod Pathol. 2015;28(1):69–79. Doi: 10.1038/modpathol.2014.82.Alkatout I, Friemel J, Sitek B, et al. Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas. Mod Pathol. 2015;28(1):69–79. Doi: 10.1038/modpathol.2014.82.Baudin E, Caron P, Lombard-Bohas C, et al. Malignant insulinoma: recommendations for characterisation and treatment. Ann Endocrinol (Paris). 2013;74(5–6):523–533. Doi: 10.1016/j.ando.2013.07.001.Baudin E, Caron P, Lombard-Bohas C, et al. Malignant insulinoma: recommendations for characterisation and treatment. Ann Endocrinol (Paris). 2013;74(5–6):523–533. Doi: 10.1016/j.ando.2013.07.001.

The authors declare that there are no conflicts of interest present.